BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29199692)

  • 1. Anaplastic lymphoma kinase immunohistochemistry in lung adenocarcinomas: Evaluation of performance of standard manual method using D5F3 antibody.
    Jain D; Jangra K; Malik PS; Arulselvi S; Madan K; Mathur S; Sharma MC
    Indian J Cancer; 2017; 54(1):209-213. PubMed ID: 29199692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma.
    Ying J; Guo L; Qiu T; Shan L; Ling Y; Liu X; Lu N
    Ann Oncol; 2013 Oct; 24(10):2589-2593. PubMed ID: 23904459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC).
    Shen Q; Wang X; Yu B; Shi S; Liu B; Wang Y; Xia Q; Rao Q; Zhou X
    Lung Cancer; 2015 Dec; 90(3):492-8. PubMed ID: 26477969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.
    Marchetti A; Di Lorito A; Pace MV; Iezzi M; Felicioni L; D'Antuono T; Filice G; Guetti L; Mucilli F; Buttitta F
    J Thorac Oncol; 2016 Apr; 11(4):487-95. PubMed ID: 26916631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study.
    Wang Q; Zhao L; Yang X; Wei S; Zeng Y; Mao C; Lin L; Fu P; Lyu L; Li Z; Xiao H
    Lung Cancer; 2016 May; 95():39-43. PubMed ID: 27040850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative analysis of immunohistochemistry and fluorescent
    Wagle PB; Jambhekar NA; Kumar R; Prabhash K; Pramesh CS; Desai SB; Noronha V; Karimundackal G; Shah A; Joshi A; Laskar SG; Jiwnani S; Pai T; Agarwal JP
    Indian J Cancer; 2017; 54(1):148-154. PubMed ID: 29199679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
    Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A standardized protocol for detection of ALK protein expression and gene fusion in lung adenocarcinoma cytologic specimens].
    Wang Z; Wu X; Shi Y; Han X; Cheng G; Li L; Mu X; Zhang Y; Cui D; Zhang L; Fan Z; Zhu G; Ma L; Yang L; Di J; Liu D
    Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):742-8. PubMed ID: 26813592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement.
    Shan L; Lian F; Guo L; Yang X; Ying J; Lin D
    Diagn Pathol; 2014 Jan; 9():3. PubMed ID: 24422905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma.
    Rosenblum F; Hutchinson LM; Garver J; Woda B; Cosar E; Kurian EM
    Cancer Cytopathol; 2014 Nov; 122(11):810-21. PubMed ID: 25099128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas.
    Lantuejoul S; Rouquette I; Blons H; Le Stang N; Ilie M; Begueret H; Grégoire V; Hofman P; Gros A; Garcia S; Monhoven N; Devouassoux-Shisheboran M; Mansuet-Lupo A; Thivolet F; Antoine M; Vignaud JM; Penault-Llorca F; Galateau-Sallé F; McLeer-Florin A
    Eur Respir J; 2015 Jul; 46(1):207-18. PubMed ID: 25929957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization.
    Williams AS; Greer W; Bethune D; Craddock KJ; Flowerdew G; Xu Z
    Virchows Arch; 2016 Nov; 469(5):533-540. PubMed ID: 27562706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel, highly sensitive ALK antibody 1A4 facilitates effective screening for ALK rearrangements in lung adenocarcinomas by standard immunohistochemistry.
    Gruber K; Kohlhäufl M; Friedel G; Ott G; Kalla C
    J Thorac Oncol; 2015 Apr; 10(4):713-6. PubMed ID: 25789835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent.
    Conklin CM; Craddock KJ; Have C; Laskin J; Couture C; Ionescu DN
    J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23196275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer.
    Cutz JC; Craddock KJ; Torlakovic E; Brandao G; Carter RF; Bigras G; Deschenes J; Izevbaye I; Xu Z; Greer W; Yatabe Y; Ionescu D; Karsan A; Jung S; Fraser RS; Blumenkrantz M; Lavoie J; Fortin F; Bojarski A; Côté GB; van den Berghe JA; Rashid-Kolvear F; Trotter M; Sekhon HS; Albadine R; Tran-Thanh D; Gorska I; Knoll JH; Xu J; Blencowe B; Iafrate AJ; Hwang DM; Pintilie M; Gaspo R; Couture C; Tsao MS
    J Thorac Oncol; 2014 Sep; 9(9):1255-63. PubMed ID: 25122422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimized immunohistochemistry using the D5F3 antibody provides a reliable test for identification of ALK-positive lung adenocarcinomas.
    Vinciguerra GLR; Scarpino S; Pini B; Cippitelli C; Fochetti F; Ruco L
    Virchows Arch; 2017 Jul; 471(1):123-127. PubMed ID: 28516197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib.
    Thorne-Nuzzo T; Williams C; Catallini A; Clements J; Singh S; Amberson J; Dickinson K; Gatalica Z; Ho SN; Loftin I; McElhinny A; Towne P
    J Thorac Oncol; 2017 May; 12(5):804-813. PubMed ID: 28147239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Manual immunohistochemistry for detecting ALK gene fusion antibody in 519 cases of non-small lung cancer].
    Gu X; Wu JY; He XM; He P; Fu XG; Lin YE; Li GQ; Hao Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2015 Oct; 35(10):1440-5. PubMed ID: 26547338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anaplastic lymphoma kinase-positive adenocarcinoma of lung: a cytopathologic analysis].
    Chen Y; Gao L; Wang Y; Gui X; Zhang H; Wang L; Gu L; Feng L; Wu J; Yang W; Song Y; Zeng H; Zhang J; Bai Q; Zhou X; Ping B
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):628-32. PubMed ID: 26705277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays.
    Marchetti A; Pace MV; Di Lorito A; Canarecci S; Felicioni L; D'Antuono T; Liberatore M; Filice G; Guetti L; Mucilli F; Buttitta F
    Lung Cancer; 2016 Sep; 99():11-6. PubMed ID: 27565907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.